ATYR
aTyr Pharma, Inc.
There isn't enough reported data to score ATYR yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ATYR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ATYR's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ATYR PE Valuation
ATYR has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ATYR Forward outlook
There aren't enough analyst estimates for ATYR to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ATYR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$22.23 | +$10.57 |
| Q2 2026 | -$25.20 | +$6.40 |
| Q1 2026 | -$29.60 | +$2.40 |
| Q4 2025 | -$32.00 | +$2.40 |
| Q3 2025 | -$32.80 | +$4.00 |
| Q2 2025 | -$31.60 | +$4.00 |
| Q1 2025 | -$32.00 | +$3.20 |
| Q4 2024 | -$34.40 | +$3.20 |
ATYR is still losing money, but far less than before: $22.23 per share over the past year, against $293.20 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ATYR on earnings quality, reporting a profit while its opponent remains loss making.
ATYR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2020 | $2.1M | +1326% |
ATYR's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -14076% | N/A |
| Q1 2024 | -7079% | N/A |
| Q3 2023 | -3574% | N/A |
| Q4 2020 | -241% | +3900 points |
| Q3 2020 | -4400% | N/A |
| Q2 2020 | -3343% | N/A |
| Q1 2020 | 23% | N/A |
| Q4 2019 | -4140% | N/A |
ATYR's operating margin was −14076% last quarter, down 9676 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ATYR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.6M | +$11M |
| Q2 2026 | -$9.4M | +$4.5M |
| Q1 2026 | -$12.7M | +$2.8M |
| Q4 2025 | -$12.2M | +$930K |
| Q3 2025 | -$20.5M | -$7.3M |
| Q2 2025 | -$13.9M | +$6.6M |
| Q1 2025 | -$15.4M | +$7M |
| Q4 2024 | -$13.2M | -$2.1M |
ATYR has burned cash in almost every quarter: −$44M over the past year, against −$63M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ATYR on cash generation, producing positive trailing cash flow while its opponent burns cash.
ATYR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +4.9K shares |
| 1 year | +1.1% | +27.8K shares |
| 3 years | +78% | +1.1M shares |
| 5 years | +918% | +2.2M shares |
ATYR has 2M diluted shares, up 1.1% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ATYR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ATYR Net Leverage
ATYR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ATYR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.3 | Oversold |
| Stochastic | 8.9 | Oversold |
ATYR's weekly RSI is 29 (oversold) and its Stochastic is 9 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ATYR PE vs Healthcare Sector
ATYR has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ATYR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.08 | 23% below |
| 20 week MA | $15.3 | 59% below |
| 50 week MA | $24.0 | 74% below |
| 100 week MA | $82.4 | 92% below |
| 200 week MA | $80.1 | 92% below |
ATYR is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ATYR on trend strength, trading above more of its moving averages.
ATYR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $168.0 | $169.2 | +0.7% |
| 2021 | $169.2 | $314.0 | +86% |
| 2022 | $314.0 | $85.6 | -73% |
| 2023 | $85.6 | $56.4 | -34% |
| 2024 | $56.4 | $149.6 | +165% |
| 2025 | $149.6 | $29.7 | -80% |
| 2026 YTD | $29.7 | $6.21 | -79% |
ATYR's yearly returns have swung widely, from +165% in 2024 to −80% in 2025. It's down 79% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ATYR on returns for 2026, with the stronger performance.